PLR、NLR对食管鳞癌放化疗/放疗患者预后的影响

李科; 李涛; 吕家华; 肖苓; 刘晓

doi:10.16689/j.cnki.cn11-9349/r.2020.03.015

PDF(1144 KB)

肿瘤代谢与营养电子杂志 ›› 2020, Vol. 7 ›› Issue (3) : 327-332. DOI: 10.16689/j.cnki.cn11-9349/r.2020.03.015

论著

PLR、NLR对食管鳞癌放化疗/放疗患者预后的影响

李科1，李涛2，吕家华2，肖苓3，刘晓1

作者信息 +

Correlation between PLR, NLR and the prognosis of patients with esophageal squamous cell carcinoma undergoing chemoradiotherapy or radiotherapy

Li Ke1, Li Tao2, Lyu Jiahua2, Xiao Ling3, Liu Xiao1

Author information +

文章历史 +

摘要

目的探讨治疗前血液炎性反应标志物：血小板与淋巴细胞比值、中性粒细胞与淋巴细胞比值对食管鳞癌放化疗/放疗患者预后的影响。方法回顾性分析2012年3月至2017年11月在四川省肿瘤医院行放化疗/放疗并经病理诊断明确的143例ESCC患者的临床病理资料及随访资料。通过ROC曲线的约登指数分别确定血小板与淋巴细胞比值（PLR）和中性粒细胞与淋巴细胞比值（NLR）的界限值，并分别将患者分为高值组和低值组。χ2检验比较不同分组之间的差异，采用Kaplan-Meier法计算总生存，并采用log-rank test进行单因素分析，Cox回归模型进行多因素分析。结果利用ROC曲线求得最佳PLR、NLR界值分别为196.67、3.55，低PLR组（<196.67）为120例，高PLR组（≥196.67）为23例；低NLR组（<3.55）为96例，高NLR组（≥3.55）为47例。放化疗/放疗前PLR和NLR水平与性别、年龄、肿瘤长度、T分期、N分期等临床病理特征均无关（P>0.05）。单因素分析显示T分期、N分期、治疗方式、PLR及NLR对ESCC患者的OS有影响（P<0.05）。多因素分析显示：PLR、治疗方式以及T分期是影响ESCC患者OS的独立预后因素（P<0.05），PLR比NLR更能预测ESCC患者预后。结论 PLR和NLR可预测ESCC患者的预后，PLR还可作为影响患者OS的独立预后因素。

Abstract

Objective To investigate the effect between platelet to lymphocyte ratio (PLR), neutrophil to lymphocyte ratio (NLR) and the prognosis of patients with esophageal squamous cell carcinom(ESCC) a undergoing chemoradiotherapy or radiotherapy. Methods Retrospective analysis was performed for 143 cases with histologically confirmed ESCC that underwent chemoradiotherapy or radiotherapy from March 2012 to November 2017. The cutoff values of NLR and PLR were determined by ROC curve, and the patients were divided into high value group and low value group respectively. The chi-square test was used to compare the differences between different groups；Kaplan-Meier method was used to calculate the overall survival (OS)；log-rank test method was used for univariate analysis and Cox regression model for multivariate analysis. Results ROC curve analysis showed that PLR ＝189, NLR=3.55 were optimal cut-off values, 120 cases in low PLR group (<196.67), 23 cases in high PLR group (≥ 196.67)；96 cases in low NLR group (<3.55), 47 cases in high NLR group (≥ 3.55).The level of PLR and NLR before chemoradiotherapy or radiotherapy was not related to sex, age, tumor length, T stage, N stage and other clinicopathological features(P>0.05).Univariate analysis showed that T stage, N stage, treatment method, PLR and NLR are correlated with the overall survival of patients with esophageal squamous cell carcinoma before chemoradiotherapy or radiotherapy(P<0.05). Multivariate analysis revealed that the PLR, treatment method and T stage were identified as independent prognostic factors for the overall survival of ESCC patients(P<0.05), PLR is better than NLR in predicting the prognosis of esophageal cancer patients. Conclusion PLR and NLR might predict the prognosis of ESCC patients. PLR could be an independent prognostic factor for ESCC.

引用本文

EndNote

Ris (Procite)

Bibtex

导出引用

李科，李涛，吕家华，肖苓，刘晓. PLR、NLR对食管鳞癌放化疗/放疗患者预后的影响[J]. 肿瘤代谢与营养电子杂志. 2020, 7(3): 327-332 https://doi.org/10.16689/j.cnki.cn11-9349/r.2020.03.015

Li Ke, Li Tao, Lyu Jiahua, Xiao Ling, Liu Xiao. Correlation between PLR, NLR and the prognosis of patients with esophageal squamous cell carcinoma undergoing chemoradiotherapy or radiotherapy[J]. Electronic Journal of Metabolism and Nutrition of Cancer. 2020, 7(3): 327-332 https://doi.org/10.16689/j.cnki.cn11-9349/r.2020.03.015

参考文献

1.MANTOVANI A, ALLAVENA P, SICA A, et al. Cancer-related inflammation［J］. Nature, 2008, 454(7203):436-444.
2.COLOTTA F, ALLAVENA P, SICA A, et al. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability［J］. Carcinogenesis, 2009, 30(7):1073-1081.
3.NAKAMURA T, GASTON C L, REDDY K, et al.Inflammatory biomarkers in cancer［J］.Mediators Inflamm, 2016, 2016:7282797.
4.SUZUKI S, AKIYOSHI T, OBA K, et al.Comprehensive comparative analysis of prognostic value of systemic inflammatory biomarkers for patients with stage Ⅱ/Ⅲ colon cancer［J］. Ann Surg Oncol, 2020, 27(3):844-852.
5.SONG X, CHEN D, YUAN M, et al.Total lymphocyte count, neutrophil-lymphocyte ratio, and platelet-lymphocyte ratio as prognostic factors in advanced non-small cell lung cancer with chemoradiotherapy［J］.Cancer Manag Res, 2018, 10:6677-6683.
6.Li A, He K, GUO D, et al.Pretreatment blood biomarkers predict pathologic responses to neo-CRT in patients with locally advanced rectal cancer［J］.Future Oncol, 2019, 15(28):3233-3242.
7.LEE H J, KIM J M, CHIN Y J, et al.Prognostic value of hematological parameters in locally advanced cervical cancer patients treated with concurrent chemoradiotherapy［J］.Anticancer Res, 2020, 40(1):451-458.
8.WU Y F, CHU S C, CHANG B S, et al. Hematologic markers as prognostic factors in nonmetastatic esophageal cancer patients under concurrent chemoradiotherapy［J］.Biomed Res Int, 2019, 2019:1263050.
9.BALKWILL F, MANTOVANI A. Inflammation and cancer: back to virchow［J］. Lancet, 2001, 357(9255):539-545.
10.XIE X, LUO K J, HU Y, et al. Prognostic value of preoperative platelet-lymphocyte and neutrophil-lymphocyte ratio in patients undergoing surgery for esophageal squamous cell cancer［J］. Dis Esophagus, 2016, 29 (1):79-85.
11.LIU J S, HUANG Y, YANG X, et al. A nomogram to predict prognostic values of various inflammatory biomarkers in patients with esophageal squamous cell carcinoma［J］. Am J Cancer Res, 2015, 5(7):2180-2189.
12.GENG Y, SHAO Y, ZHU D, et al. Systemic immune-inflflammation index predicts prognosis of patients with esophageal squamous cell carcinoma: a propensity score-matched analysis［J］. Sci Rep, 2016, 6:39482.
13.LEE B M, CHUNG S Y, CHANG J S, et al.The neutrophil-lymphocyte ratio and platelet-lymphocyte ratio are prognostic factors in patients with locally advanced pancreatic cancer treated with chemoradiotherapy［J］.Gut Liver, 2018, 12(3):342-352.
14.SHEN J, ZHU Y, WU W, et al. Prognostic role of neutrophil-to-lymphocyte ratio in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy［J］.Med Sci Monit, 2017, 23:315-324.
15.SUN Y, ZHANG L. The clinical use of pretreatment NLR, PLR, and LMR in patients with esophageal squamous cell carcinoma: evidence from a meta-analysis［J］.Cancer Manag Res, 2018, 10:6167-6179.
16.SCHLESINGER M.Role of platelets and platelet receptors in cancer metastasis［J］.J Hematol Oncol, 2018, 11(1):125.
17.MENTER D G, KOPETZ S, HAWK E, et al. Platelet “first responders” in wound response, cancer, and metastasis［J］.Cancer Metastasis Rev, 2017, 36(2):199-213.
18.AMO L, TAMAYO-ORBEGOZO E, MARURI N, et al.Involvement of platelet-tumor cell interaction in immune evasion［J］. Potential role of podocalyxin-like protein 1［J］. Front Oncol, 2014, 4:245.
19.AMSEN D, HOMBRINK P, VAN LIER, et al.Tumor immunity requires border patrol to fight the enemy within［J］.Nat Immunol, 2017, 18(8):870-872.
20.FENG J F, LIU J S, HUANG Y. Lymphopenia predicts poor prognosis in patients with esophageal squamous cell carcinoma［J］.Medicine, 2014, 93 (27):e257.
21.KOU F, LU Z, LI J, et al.Pretreatment lymphopenia is an easily detectable predictive and prognostic marker in patients with metastatic esophagus squamous cell carcinoma receiving first-line chemotherapy［J］. Cancer Med, 2016, 5 (5):778-786.
22.MA J Y, KE L C, LIU Q.The pretreatment platelet-to-lymphocyte ratio predicts clinical outcomes in patients with cervical cancer: a meta-analysis［J］. Medicine (Baltimore), 2018, 97(43):e12897.
23.MIAO C, ZHU S, PAN H, et al.Combined neutrophil-platelet score and hemoglobin level predict survival in esophageal squamous cell carcinoma patients treated with chemoradiotherapy［J］.Oncotarget, 2017, 8(50):87971-87979.
24.ZHU S, MIAO C W, WANG Z T, et al.Sensitivity value of hematological markers in patients receiving chemoradiotherapy for esophageal squamous cell carcinoma［J］.Onco Targets Ther, 2016, 9:6187-6193.
25.MAYER C, DARBESFAHANI S, MEYER A S, et al. Neutrophil granulocytes in ovarian cancer induction of epithelial to mesenchymal transition and tumor cell migration ［J］. J Cancer, 2016, 7(5):546-554.
26.GAO Y, HUANG D.The value of the systematic inflammation based glasgow prognostic score in patients with gastric cancer: a literature review［J］. J Cancer Res The, 2014, 10(4):799-804.
27.HOFFMAN M, TAUGNER J, ROENGVORAPHOJ O, et al.Impact of thrombocytosis and neutrophil-to-lymphocyte ratio before start of chemoradiotherapy on patient survival in inoperable stage Ⅲ NSCLC［J］. Ann Oncol, 2019, 30 Suppl 2:ii36.
28.LI K J, XIA X F, SU M, et al.Predictive value of lymphocyte-to-monocyte ratio (LMR) and neutrophil-to-lymphocyte ratio (NLR) in patients with oesophageal cancer undergoing concurrent chemoradiotherapy［J］.BMC Cancer, 2019, 19(1):1004.